Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.

Abstract: The invention is a control system for adjusting at least one vehicle system in a plurality of vehicle systems comprising at least one polymer-based biometric sensor positioned proximate a driver for monitoring at least one vital sign of a driver of the vehicle and configured to produce data in response to changes in the at least one vital sign. The system also comprises at least one camera system positioned to view the driver. A first processing system is configured to receive sensor data and input collected by the camera system to determine a biometric state of the driver. The biometric state of the vehicle driver is then used to determine an adjustment setting for the at least one vehicle system thereby controlling the vehicle system in response to the adjustment setting in accordance with the determined biometric state of the vehicle driver.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.

Abstract: Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.

Abstract: A process for applying and storing adherent cells on a tissue culture plate 20 for preparing tissue culture plates for use in tissue culture experiments. In the process, adherent cells are removed from a flask using trypsin after being incubated in a CO2 Incubator. The cell suspension is created using the adherent cells and a liquid culture medium, which is centrifuged and tested for volume using a hemacytometer. The cell suspension is placed in the wells of a tissue culture plate 20 and then incubated. A cryopreservative is deposited into each well and the tissue culture plate is sealed with an adhesive foil cover and cryogenically preserved using liquid nitrogen. The tissue culture plate 20 is then place into a plastic, waterproof, resealable bag enabling it to be stored at −80° C. for up to 3 months and shipped without damaging the morphological or functional nature of the adherent cells.